Halozyme Therapeutics, Inc. with ticker code (HALO) have now 9 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 66 and 26 calculating the average target price we see $49.33. Now with the previous closing price of $35.00 and the analysts are correct then there would likely be a percentage uptick in value of 40.9%. The 50 day moving average now sits at $34.76 while the 200 day moving average is $44.87. The company has a market cap of 4.48B. The current share price for the company is: 34.01 USD
The potential market cap would be $6,312,036,150 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 25.38, revenue per share of 5.18 and a 11.69% return on assets.
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators’ compounds. The Company’s proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids. The Company’s commercially approved product, Hylenex recombinant (Hylenex), and its ENHANZE partners approved products and product candidates are based on rHuPH20. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that is designed to provide commercial or functional advantages. It has a commercial portfolio of proprietary products, including XYOSTED, TLANDO and NOCDURNA and partnered commercial products and ongoing product development programs with several pharmaceutical companies.
